Dysregulation of C/EBPα by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease

Human Molecular Genetics

Volumn 16, Issue 5, 2007, Pages 483-498

  Chiang, Ming Chang ^a,b   Chen, Hui Mei ^a   Lee, Yi Hsin ^a   Chang, Hao Hung ^a   Wu, Yi Chih ^a   Soong, Bing Wen ^b   Chen, Chiung Mei ^c   Wu, Yih Ru ^c   Liu, Chin San ^d   Niu, Dau Ming ^e   Wu, Jer Yuarn ^a   Chen, Yuan Tsong ^a   Chern, Yijuang ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; CITRULLINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HUNTINGTIN; HUNTINGTON PROTEIN, MOUSE; MUTANT PROTEIN; NERVE PROTEIN; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; UREA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRULLINEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; HYPERAMMONEMIA; MALE; MOTOR DYSFUNCTION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; PROTEIN RESTRICTION; UREA CYCLE; ANIMAL; BLOOD; CHEMISTRY; DIET; DISEASE COURSE; DOWN REGULATION; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PROMOTER REGION; PROTEIN BINDING; PROTEIN QUATERNARY STRUCTURE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CITRULLINE; DIET; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; HUNTINGTON DISEASE; LIVER; MALE; MICE; MIDDLE AGED; MOTOR ACTIVITY; MUTANT PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; UREA;

EID: 34047184385     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddl481     Document Type: Article

References (66)

1. Group, T.H.s.D.C.R. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
2. Reiner, A., Albin, R.L., Anderson, K.D., D'Amato, C.J., Penney, J.B. and Young, A.B. (1988) Differential loss of striatal projection neurons in Huntington disease. PNAS, 85, 5733-5737.
3. Martindale, D., Hackam, A., Wieczorek, A., Ellerby, L., Wellington, C., McCutcheon, K., Singaraja, R., Kazemi-Esfarjani, P., Devon, R., Kim, S.U. et al. (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet., 18, 150.
4. Chiang, M.-C., Lee, Y.-C., Huang, C.-L. and Chern, Y. (2005) cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem., 280, 14331-14340.
5. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
6. Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J. and Mattson, M.P. (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. PNAS, 100, 2911-2916.
7. Podolsky, S., Leopold, N.A. and Sax, D.S. (1972) Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet, 1, 1356-1358.
8. Garseth, M., Sonnewald, U., White, L.R., Rod, M., Zwart, J.A., Nygaard, O. and Aasly, J. (2000) Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: Indication of glial energy impairment in Huntington chorea, but not Parkinson disease. J. Neurosci. Res., 60, 779-782.
9. Hurlbert, M.S., Zhou, W., Wasmeier, C., Kaddis, F.G., Hutton, J.C. and Freed, C.R. (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes, 48, 649-651.
10. Stoy, N., Mackay, G.M., Forrest, C.M., Christofides, J., Egerton, M., Stone, T.W. and Darlington, L.G. (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem., 93, 611-623.
11. Underwood, B.R., Broadhurst, D., Dunn, W.B., Ellis, D.I., Michell, A.W., Vacher, C., Mosedale, D.E., Kell, D.B., Barker, R.A., Grainger, D.J. et al. (2006) Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain, 129, 877-886.
12. Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N.R., Doi, H., Kurosawa, M., Nekooki, M. and Nukina, N. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med., 10, 148.
13. Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E.E., Doherty, P., Davies, S.W. and Bates, G.P. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet., 8, 813-822.
14. Jackson, M.J., Beaudet, A.L. and O'Brien, W.E. (1986) Mammalian urea cycle enzymes. Annu. Rev. Genet., 20, 431-464.
15. Endo, F., Matsuura, T., Yanagita, K. and Matsuda, I. (2004) Clinical manifestations of inborn errors of the urea cycle and related metabolic disorders during childhood. J. Nutr., 134, 1605S-1609S, discussion 1630S-1632S, 1667S-1672S.
16. Karpuj, M.V., Becher, M.W., Springer, J.E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D. and Steinman, L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med., 8, 143-149.
17. Chou, S.-Y., Lee, Y.-C., Chen, H.-M., Chiang, M.-C., Lai, H.-L., Chang, H.-H., Wu, Y.-C., Sun, C.-N., Chien, C.-L., Lin, Y.-S. et al. (2005) CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem., 93, 310-320.
18. Havens, L.L. and Child, C.G. (1955) Recurrent psychosis associated with liver disease and elevated blood ammonia. N. Engl. J. Med., 252, 756-759.
19. De Marchi, N. and Mennella, R. (2000) Huntington's disease and its association with psychopathology. Harv. Rev. Psychiatry, 7, 278-289.
20. Lin, C.-H., Tallaksen-Greene, S., Chien, W.-M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.-J., Albin, R.L. and Detloff, P.J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet., 10, 137-144.
21. Leonard, J.V. (2001) The nutritional management of urea cycle disorders. J. Pediatr., 138, S40-S44, discussion S44-S45.
22. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
23. Wyttenbach, A., Sauvageot, O., Carmichael, J., Diaz-Latoud, C., Arrigo, A.P. and Rubinsztein, D.C. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet., 11, 1137-1151.
24. Jana, N.R., Tanaka, M., Wang, G. and Nukina, N. (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet., 9, 2009-2018.
25. Hay, D.G., Sathasivam, K., Tobaben, S., Stahl, B., Marber, M., Mestril, R., Mahal, A., Smith, D.L., Woodman, B. and Bates, G.P. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet., 13, 1389-1405.
26. Agrawal, N., Pallos, J., Slepko, N., Apostol, B.L., Bodai, L., Chang, L.W., Chiang, A.S., Thompson, L.M. and Marsh, J.L. (2005) Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl Acad. Sci. USA, 102, 3777-3781.
27. Murakami, Y., Uehara, Y., Yamamoto, C., Fukazawa, H. and Mizuno, S. (1991) Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes. Exp. Cell Res., 195, 338-344.
28. Matsubasa, T., Takiguchi, M., Matsuda, I. and Mori, M. (1994) Rat argininosuccinate lyase promoter: The dyad-symmetric CCAAT box sequence CCAATTGG in the promoter is recognized by NF-Y. J. Biochem.(Tokyo), 116, 1044-1055.
29. Luthi-Carter, R., Strand, A.D., Hanson, S.A., Kooperberg, C., Schilling, G., La Spada, A.R., Merry, D.E., Young, A.B., Ross, C.A., Borchelt, D.R. et al. (2002) Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet., 11, 1927-1937.
30. Kimura, T., Christoffels, V.M., Chowdhury, S., Iwase, K., Matsuzaki, H., Mori, M., Lamers, W.H., Darlington, G.J. and Takiguchi, M. (1998) Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBPalpha knockout mice. J. Biol. Chem., 273, 27505-27510.
31. Blobel, G.A. (2000) CREB-binding protein and p300: Molecular integrators of hematopoietic transcription. Blood, 95, 745-755.
32. Christy, R.J., Kaestner, K.H., Geiman, D.E. and Lane, M.D. (1991) CCAAT/ enhancer binding protein gene promoter: Binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc. Natl Acad. Sci. USA, 88, 2593-2597.
33. Kosenko, E., Kaminsky, Y., Kaminsky, A., Valencia, M., Lee, L., Hermenegildo, C. and Felipo, V. (1997) Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic. Res., 27, 637-644.
34. Cowan, C.M. and Raymond, L.A. (2006) Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol., 75, 25-71.
35. Ollinger, K. and Roberg, K. (1997) Nutrient deprivation of cultured rat hepatocytes increases the desferrioxamine-available iron pool and augments the sensitivity to hydrogen peroxide. J. Biol. Chem., 272, 23707-23711.
36. Bergamini, E., Cavallini, G., Donati, A. and Gori, Z. (2003) The anti-ageing effects of caloric restriction may involve stimulation of macroautophagy and lysosomal degradation, and can be intensified pharmacologically. Biomed. Pharmacother., 57, 203-208.
37. Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G., Scaravilli, F., Easton, D.F., Duden, R., O'Kane, C.J. et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet., 36, 585-595.
38. Iwata, A., Christianson, J.C., Bucci, M., Ellerby, L.M., Nukina, N., Forno, L.S. and Kopito, R.R. (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl Acad. Sci. USA, 102, 13135-13140.
39. Yamamoto, A., Cremona, M.L. and Rothman, J.E. (2006) Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol., 172, 719-731.
40. Curis, E., Nicolis, I., Moinard, C., Osowska, S., Zerrouk, N., Benazeth, S. and Cynober, L. (2005) Almost all about citrulline in mammals. Amino acids, 29, 177-205.
41. Suzuki, Y., Tsunoda, T., Sese, J., Taira, H., Mizushima-Sugano, J., Hata, H., Ota, T., Isogai, T., Tanaka, T., Nakamura, Y. et al. (2001) Identification and characterization of the potential promoter regions of 1031 kinds of human genes. Genome Res., 11, 677-684.
42. Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmant, G., Troy, A.E., McKeon, C., Darlington, G.J. and Spiegelman, B.M. (1999) Cross-regulation of C/EBP[alpha] and PPAR[gamma] controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell, 3, 151.
43. Wang, N.D., Finegold, M.J., Bradley, A., Ou, C.N., Abdelsayed, S.V., Wilde, M.D., Taylor, L.R., Wilson, D.R. and Darlington, G.J. (1995) Impaired energy homeostasis in C/EBP alpha knockout mice. Science, 269, 1108-1112.
44. Testa, A., Donati, G., Yan, P., Romani, F., Huang, T.H.M., Vigano, M.A. and Mantovani, R. (2005) Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J. Biol. Chem., 280, 13606-13615.
45. Gutekunst, C.A., Norflus, F. and Hersch, S.M. (2000) Recent advances in Huntington's disease. Curr. Opin. Neurol., 13, 445-450.
46. Felipo, V. and Butterworth, R.F. (2002) Mitochondrial dysfunction in acute hyperammonemia. Neurochem. Int., 40, 487-491.
47. Szerb, J.C. and Butterworth, R.F. (1992) Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog. Neurobiol., 39, 135-153.
48. Robinson, M.B., Hopkins, K., Batshaw, M.L., McLaughlin, B.A., Heyes, M.P. and Oster-Granite, M.L. (1995) Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Brain Res. Dev. Brain Res., 90, 35-44.
49. Verhagen Metman, L., Morris, M.J., Farmer, C., Gillespie, M., Mosby, K., Wuu, J. and Chase, T.N. (2002) Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology, 59, 694-699.
50. Marcaida, G., Felipo, V., Hermenegildo, C., Minana, M.D. and Grisolia, S. (1992) Acute ammonia toxicity is mediated by the NMDA type of glutamate receptors. FEBS Lett., 296, 67-68.
51. Hermenegildo, C., Marcaida, G., Montoliu, C., Grisolia, S., Minana, M.D. and Felipo, V. (1996) NMDA receptor antagonists prevent acute ammonia toxicity in mice. Neurochem. Res., 21, 1237-1244.
52. Schiefer, J., Landwehrmeyer, G.B., Luesse, H.G., Sprunken, A., Puls, C., Milkereit, A., Milkereit, E. and Kosinski, C.M. (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord., 17, 748-757.
53. Bialostosky, K., Wright, J.D., Kennedy-Stephenson, J., McDowell, M. and Johnson, C.L. (2002) Dietary intake of macronutrients, micronutrients, and other dietary constituents: United States 1988-94. Vital Health Stat., 11, 1-158.
54. Wexler, N.S., Lorimer, J., Porter, J., Gomez, F., Moskowitz, C., Shackell, E., Marder, K., Penchaszadeh, G., Roberts, S.A., Gayan, J. et al. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl Acad. Sci. USA, 101, 3498-3503.
55. Squitieri, F., Cannella, M. and Simonelli, M. (2002) CAG mutation effect on rate of progression in Huntington's disease. Neurol. Sci., 23 (Suppl. 2), S107-S108.
56. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
57. Wu, J.Y., Kao, H.J., Li, S.C., Stevens, R., Hillman, S., Millington, D. and Chen, Y.T. (2004) ENU mutagenesis identifies mice with mitochondrial branched-chain aminotransferase deficiency resembling human maple syrup urine disease. J. Clin. Invest., 113, 434-440.
58. Lin, W.D., Wu, J.Y., Lai, C.C., Tsai, F.J., Tsai, C.H., Lin, S.P. and Niu, D.M. (2001) A pilot study of neonatal screening by electrospray ionization tandem mass spectrometry in Taiwan. Acta Paediatr. Taiwan, 42, 224-230.
59. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
60. Borrell-Pages, M., Canals, J.M., Cordelieres, F.P., Parker, J.A., Pineda, J.R., Grange, G., Bryson, E.A., Guillermier, M., Hirsch, E., Hantraye, P. et al. (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest., 116, 1410-1424.
61. Liu, F.-C., Wu, G.-C., Hsieh, S.-T., Lai, H.-L., Wang, H.-F., Wang, T.-W. and Chern, Y. (1998) Expression of type VI adenylyl cyclase in the central nervous system: Implication for a potential regulator of multiple signals in different neurotransmitter systems. FEBS Lett., 436, 92-98.
62. Lee, Y.C., Chien, C.L., Sun, C.N., Huang, C.L., Huang, N.K., Chiang, M.C., Lai, H.L., Lin, Y.S., Chou, S.Y., Wang, C.K. et al. (2003) Characterization of the rat A2A adenosine receptor gene: A 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. Eur. J. Neurosci., 18, 1786-1796.
63. Yu, B., Thompson, G.D., Yip, P., Howell, P.L. and Davidson, A.R. (2001) Mechanisms for intragenic complementation at the human argininosuccinate lyase locus. Biochemistry, 40, 15581-15590.
64. Hao, G., Xie, L. and Gross, S.S. (2004) Argininosuccinate synthetase is reversibly inactivated by S-nitrosylation in vitro and in vivo. J. Biol. Chem., 279, 36192-36200.
65. Lai, H.L., Yang, T.H., Messing, R.O., Ching, Y.H., Lin, S.C. and Chern, Y. (1997) Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response. J. Biol. Chem., 272, 4970-4977.
66. Wanker, E.E., Scherzinger, E., Heiser, V., Sittler, A., Eickhoff, H. and Lehrach, H. (1999) Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Meth. Enzymol., 309, 375-386.